Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake
Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.
Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib
The latest drug development news and highlights from our US FDA Performance Tracker.
Zelnorm Returning To US Market With Broad IBS-C Indication
US FDA limiting use of Zelnorm, originally pulled from the market in 2007 by its then-sponsor Novartis, to adult women who are at low CV risk, but tegaserod is not restricted to patients who are severely symptomatic for IBS-C.